Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Background: Outcomes of classical Hodgkin lymphoma (cHL) remain poor in older adults (OA) with 5- year progression free survival (PFS) of 60% even with curative therapy (Cheng, et al. Blood Advances 2022). In the ECHELON-1 study, brentuximab-AVD led to higher incidence of toxicities in OA without any significant benefit in PFS compared to ABVD (Evens, et al. Haematologica 2022).
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
